MESSE-BERLIN
Premiere at CE China : The Chinese retail giant Suning, strategic partner of CE China, has seized the opportunity to present eight new products of its Biu product line for smart home appliances at the CE China in Guangzhou. On this occasion, fans of Biu were invited to the first ever Biu fan festival to attend the launch.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190923005490/en/
Behind closed curtains, selected Biu-fans were the first to learn about the premieres of intelligent smart home products at the booth of Suning on the trade show. Among others, Suning presented the new Biu air conditioner as a “pro version”, the "Little Dolphin" electric water heater and the "Little Seashells" gas water heater. Suning representatives also showed, how the different devices connect with each other.
According to Suning, Biu will continue to focus on smart products, smart home solutions, and services in order to bring users a full range of smart solutions. The company further announced to launch a large capacity multi-door Biu refrigerator and a Biu washing machine in October.
Jens Heithecker, IFA Executive Director and CE China Chairman, said: “Suning’s Biu product premieres here at CE China are a great honour and an example of how to get large attention to innovative concepts. Besides, it is yet another proof that we have chosen the right place and date for our show.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20190923005490/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons to acquire AOL following $2.8B debt financing29.10.2025 16:30:00 CET | Press release
Acquisition positions historic brand for its next phase of growth Technology company Bending Spoons today announced that it has entered into a definitive agreement to acquire AOL, the web portal and email provider, from Yahoo. The acquisition is expected to close by the end of the year, subject to customary closing conditions and regulatory approvals. “AOL is an iconic, beloved business that’s in good health, has stood the test of time, and we believe has unexpressed potential,” said Bending Spoons CEO and co-founder, Luca Ferrari. “By our estimation, AOL is one of the top ten most-used email providers in the world, with a highly retained customer base counting around 8 million daily and 30 million monthly active users. We intend to invest significantly to help the product and the business flourish. Bending Spoons has never sold an acquired business—we’re confident we’re the right long-term steward for AOL, and look forward to serving its large, loyal customer base for many years to co
Doha Debates Questions Whether Modern Architecture Contributes to Cultural Decline29.10.2025 16:15:00 CET | Press release
Episode two of flagship debate show asks: Have we lost touch with beauty in the world we have built? This week, Qatar Foundation’s Doha Debates examines how architecture reflects and shapes cultural values on their flagship show, Doha Debates. The second episode of the new season asks: Has modern architecture redefined beauty and tradition, or contributed to its decline? This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029822479/en/ Doha Debates brought together a distinguished group of architects, thinkers, and creatives to question whether modern architecture contributes to cultural decline. From left: Sundus Saeed, Ameer Sadi, Sara Akbar, Carl Jambo, Huda Muazzam Iqbal, Tariq Khayyat, Bidisha Sinha, Dareen Abughaida, Carl W. Korsnes, Marwa Al-Sabouni, Leen Nedal Yamin, Wahed Shaik, Lina Ayman Darwish, Mudassar Raza Shakir, and John Carlos Burog. (Photo: AETOSWire) Moderated by Dareen Abughaida, the debate brings students
SK pharmteco and LOTTE BIOLOGICS Sign Strategic Partnership to Strengthen Global ADC CDMO Capabilities29.10.2025 15:35:00 CET | Press release
Two global CDMO leaders have joined forces to strengthen their presence in the rapidly growing antibody-drug conjugate (ADC) market.The collaboration will deliver integrated, one-stop CDMO services spanning antibody drug substance, linker–payload production, and bioconjugation, supported by joint marketing based on deep ADC expertise. SK pharmteco and LOTTE BIOLOGICS have announced that they have signed a Letter of Intent (LOI) for a strategic collaboration to strengthen their competitiveness in the global antibody-drug conjugate (ADC) market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029483889/en/ Leaders from SK pharmteco and LOTTE BIOLOGICS at the LOTTE BIOLOGICS booth at CPHI Frankfurt, Germany, following the signing of the strategic collaboration Letter of Intent on October 29, 2025. From left to right: Joon Chang, CBO, LOTTE BIOLOGICS; Jiwon Chun, CGO, LOTTE BIOLOGICS; Kern Chang, CTO, LOTTE BIOLOGICS; Yooyeol
Phenom Named Strategic Leader in 2025 Fosway 9-Grid™ for Talent & People Success for Second Consecutive Year29.10.2025 14:30:00 CET | Press release
Positioning Recognises Phenom Applied AI Phenom, an applied AI company that helps organizations hire faster, develop better and retain longer, has been named a Strategic Leader in the 2025 Fosway 9-Grid™ for Talent and People Success for the second consecutive year, changing their position by demonstrating increased performance for enterprises while lowering the total cost of ownership. The placement is a testament to the value delivered by its AI, automation and experience approach. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029195746/en/ Phenom has been named a Strategic Leader in the 2025 Fosway 9-Grid™ for Talent and People Success for the second consecutive year, changing their position by demonstrating increased performance for enterprises while lowering the total cost of ownership. The placement is a testament to the value delivered by its AI, automation and experience approach. Fosway Group identifies Strategi
Ferring Pharmaceuticals to Explore Strategic Options for Rebyota®29.10.2025 14:00:00 CET | Press release
As part of our ongoing transformation to sharpen our focus, we have decided to explore strategic options for Rebyota® (faecal microbiota, live – jslm). To date, more than five thousand patients suffering from recurrent Clostridioides difficile infection (rCDI) have found new hope when treated with Rebyota®. Without commercial critical mass in this therapy area at Ferring, we believe that this first-in-class, innovative product could benefit many more patients with a new approach to its continued commercialisation. As a result, Ferring will reduce commercial efforts in the United States while ensuring uninterrupted access for patients. Approved by the U.S. Food and Drug Administration (FDA) in 2022, Rebyota® was the first FDA-approved faecal microbiota transplant, indicated for the prevention of rCDI in adults following antibiotic treatment for recurrent CDI. This milestone marked a significant advancement in understanding the role of the human microbiome in health and disease. Ferring
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom